Details of the Drug

General Information of Drug (ID: DM87XVD)

Drug Name
ET140202
Indication
Disease Entry ICD 11 Status REF
Hepatocellular carcinoma 2C12.02 Phase 1 [1]
Liver cancer 2C12 Phase 1 [2]
Drug Type
CAR-T cell therapy
Cross-matching ID
TTD ID
D4K2OF

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Alpha-fetoprotein (AFP) TTCFEA1 FETA_HUMAN Not Available [2]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

References

1 ClinicalTrials.gov (NCT03998033) An Open-Label, Dose Escalation, Multi-Center Phase I/II Research Trial to Assess the Safety of ET140202 T Cells and Determine the Recommended Phase II Dose ("RP2D") in Adults With Advanced Hepatocellular Carcinoma ("HCC"). U.S.National Institutes of Health.
2 ClinicalTrials.gov (NCT03965546) Clinical Study of ET 140202 -T Cell Combined With TAE or Sorafenib in the Treatment of Advanced Liver Cancer. U.S.National Institutes of Health.